Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

NCT06113302 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT06113302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06113302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2024
Completion date
June 2, 2028
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes